T1	Participants 13 29	multiple myeloma
T2	Participants 165 225	Cooperative Group of Study and Treatment of Multiple Myeloma
T3	Participants 320 341	multiple myeloma (MM)
T5	Participants 721 772	stage II patients were uniformly treated with MPH-P
T6	Participants 777 870	stage III patients were randomised between MPH-P and four courses of combination chemotherapy
T4	Participants 475 691	Patients with untreated stage I MM (defined according to Durie and Salmon) were randomised between being followed without cytostatics until the disease progressed and receiving six courses of melphalan and prednisone
